To investigate the role of family history, race/ethnicity, and genetics in prostate cancer (PCa) screening.
We conducted a systematic review of articles from January 2013 through September 2023 that focused on the association of race/ethnicity and genetic factors on PCa detection. Of 10,815 studies, we identified 43 that fulfilled our pre-determined PICO (Patient, Intervention, Comparison and Outcome) criteria.
Men with ≥1 first-degree relative(s) with PCa are at increased risk of PCa, even with negative imaging and/or benign prostate biopsy. Black men have higher PCa risk, while Asian men have lower risk. Most of the differences in risks are attributable to environmental and socioeconomic factors; however, genetic differences may play a role. Among numerous pathogenic variants that increase PCa risk, BRCA2, MSH2, and HOXB13 mutations confer the highest risk of PCa. Polygenic risk score (PRS) models identify men at higher PCa risk for a given age and PSA; these models improve when considering other clinical factors and when the model population matches the study population's ancestry.
Family history of PCa, race/ethnicity, pathogenic variants (particularly BRCA2, MSH2, and HOXB13), and PRS are associated with increased PCa risk and should be considered in shared decision-making to determine PCa screening regimens.
Urologic oncology. 2024 Jul 15 [Epub ahead of print]
Nathan J Graham, Lesley H Souter, Simpa S Salami
Section of Urology, University of Chicago, Chicago, IL. Electronic address: ., Nomadic E.B.M. Methodology. Electronic address: ., Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: .